Summary The proliferation rate (as assessed by Ki67 expression) and expression of oestrogen-regulated progesterone receptor (PR) was studied in normal post-menopausal breast epithelium. Normal breast epithelium from patients receiving hormone replacement therapy (HRT) at the time of surgery containing either oestrogen alone (E2) or oestrogen and progesterone combined activities (E2 + P) was also studied, as HRT has been linked to an increased breast cancer risk. Samples of breast tissue. containing normal epithelium. from 185 patients undergoing surgery for benign or malignant disease were immunocytochemically stained for PR and Ki67. The percentage of labelled cells was expressed as the labelling index (LI). The median Ki67 Li in normal post-menopausal breast epithelium was 0.19 and median PR LI was 4.75, and both were unaffected by patient age, duration of menopause or if the tissue sample originated from a breast with benign or malignant disease. Proliferation did not alter significantly in patients taking HRT (P = 0.61); however, PR expression was up-regulated in both E2 and E2 + P users (P = 0.01). The dose and duration of HRT had no effect on either parameter. A possible attenuation of sensitivity to oestradiol-induced proliferation but not to PR expression occurs in the post-menopausal breast.
Reduced circulatinc oestradiol is responsible for manv of the unpleasant symptoms of the menopause. including hot flushes. sex ere perspiration and genital tract atrophy (Greendale and Judd. 1993) . More serious health risks include an increased incidence of cardioxascular disease (Sullixvan and Foxlkes. 1996) and osteoporosis (Greendale and Judd. 1993) . Howexer. the menopause appears to confer some protection upon breast cancer risk. Breast cancer incidence in >-omen increases 'ith age. but the rate of increase slowxs sharply oxer the age of 50 (Key and Pike. 1988) .
Additionally. in A-omen surgically induced to the menopausal state. future breast cancer risk is reduced by up to 60%s (Trichopoulos et al. 1972) . Hormone replacement therapy (HRT) . increasingly prescribed to treat menopausal sy mptoms (Moorhead et al. 1997) . contains either oestrogen (mainly oestradiol) alone (E,) or oestrogen and progesterone actixities combined (E, + Pg).
Concern has been raised that prolonging exposure of the postmenopausal breast to oestradiol (i.e. HRT) could promote breast cancer (Howxell et al. 1995) . Indeed. data suggest that prolonged use of HRT increases breast cancer incidence (Bergkvist et al. 1989 : Colditz et al. 1995 : Beral et al. 1997 ). An animal model. used to predict the effects of HRT upon human post-menopausal breast. has demonstrated that primate mammarx gland proliferation is sigmficantlv increased in response to HRT (Cline et al. 1996) . Hoxexver. the effect of HRT upon normal human breast tissue remains unknowxn. The aim of the present study wxas to determine the range of epithelial proliferation in normal breast epithelium from a large group of post-menopausal wxomen and hox-this wxas effected bv HRT. We also studied progesterone receptor expression as a marker of oestrogen responsiveness.
MATERIALS AND METHODS Patients
A retrospective studx of 185 women w-ho had undergone breast biopsy or surgerx at the Unixersity Hospital of South Manchester for malignant (n = 124) or benian breast disease (n = 61) was carred out. Menopausal status. length of menopause. details of HRT. familx history of breast disease. pathology of the tissue sample and parity at time of surgery A-ere obtained from the clinical notes and from the patient's GP. Women x-ere considered menopausal if it A-as documented that their menstrual cycles had ceased for at least 1 year. or if they w-ere oxver 50 and had been hN-sterectomized 
Ki67 labelling
Antioen retriexal xxas achieved bx a microwaxe method (Bromlev et al. 1996) . and endogenous peroxidase activity blocked by incubation in 0.3%' (x/x) hydrogen peroxide in phosphate-buffered saline (PBS) for 15 min. Slides were rinsed in PBS and tissue blocked with 0.5%7 casein in PBS for 1 h at room temperature (RT) followed by incubation xxith rabbit affinity purified anti-Ki67 poiyclonal antibody (Dako) at 1:100 in PBS for 30min (RT (Wellings et al. 1975 ). This also allow s comparison with many of the studies of premenopausal breast. which considered lobular epithelium only (Anderson et al. 1982 : Potten et al. 1988 : Williams et al. 1991 Figure 1A ) and found to be unrelated to patient age (within the range of 49-68 years) (n = Il1. rho = 0.002. P = 0.49). There was an insignificant trend tow-ards a decrease in Ki67 LI with an increase in length of time since the menopause (n = 86. rho = -0. 173. P = 0.06). Tissue samples from 100 (90%c) control patients A-ere assayed for PR expression (Figure 1 B) . Expression was unaffected by patient age (n = 100. rho = 0.07. P = 0.25) and the length of time since menopause (n = 78. rho = 0.112. P = 0.16). In control patients normal breast tissue taken adjacent to a benign lesion showed no difference compared with tissue taken adjacent to a malignant lesion in either the Ki67 LI (benign lesions. Tissue samples from all patients receiving, HRT were assayed for Ki67 expression. There was no significant difference betx-een Ki67 LI in patients receiving E or E, + P HRT and the control group (K-WA P = 0.61 ) ( Figure 1A) . PR LIs in patients takin, both types of HRT were significantly higher than the control group (K-W P = 0.01) ( Figure 1B (Meyer and Connor. 1982: Walker et al. 1991) . Oestradiol is one of the most potent stimulators of epithelial proliferation in the premenopausal breast and the severely reduced oestradiol levels present after the menopause presumably result in a lack of British Joumal of Cancer (1998) 78(7), [945] [946] [947] [948] [949] Statistics A i J. -stimulation and the lowered proliferation rates that we have demonstrated. It is well documented that age also exerts a significant negative effect upon proliferation in premenopausal (Meyer 1977 : Anderson et al. 1982 : Potten et al. 1988 ) and postmenopausal (Mever and Connor. 1982) breast epithelium. Howvever. in this laruer studv. we were unable to find anv influence of age upon any of the parameters measured in post-menopausal breast. Although the mechanism of the age effect remains unknown. our findings imply that the reduction in proliferation with increasing age may reach a plateau during the climacteric stage of menopause or at its commencement. There was a slight trend towards a reduction in proliferation with an increase in the number of months since the menopause: however. this remained insianificant.
We found that PR expression is maintained in the postmenopausal breast. although at a low-er level than that in premenopausal women. in whom PR LI averages from 12.60%e in the follicular phase to 16.45%-in the luteal phase of the menstrual cycle (McMichael-Phillips et al. 1996) . Oestradiol up-regulates PR expression in the epithelial elements of normal human breast xenografts (Laidlaw et al. 1995) . Recent evidence sugaests that PR expression is sensitive to low levels of oestradiol and higher levels are required to generate a proliferative response (Clarke et al. 1997) . This could explain the reasonably high expression of PR in post-menopausal breast epithelium compared with the lowered rate of proliferation.
The use of exogenous hormones (e.g. the oral contraceptive) increases epithelial proliferation in normal premenopausal breast (W-Illiams et al. 1991 : Chancg et al. 1995 Additionally. HRT increases proliferation of the endometrium. which is also an oestrogen-responsive tissue (Whitehead et al. 1981) . The use of HRT (E, or E,+ P) by our patients did not increase their breast epithelial proliferation index. suggesting that. postmenopausally. the breast may be less sensitive to oestrocen stimulation. A further explanation is that HRT failed to raise serum oestradiol to levels sufficiently high to stimulate proliferation. although levels were sufficient to treat menopausal symptoms. Serum samples from patients in this study were unavailable. but previous studies with a range of HRT preparations have been shown to raise serum oestradiol levels to those found in premenopausal women during the follicular phase of the menstrual cycle (Lind et al. 1979 : Whittaker et al. 1980 . and follicular phase oestradiol doses have been shown to increase siognificantly proliferation of normal premenopausal breast xenografts (Laidlaw et al. 1995) . Although some patients in our study were receiving quite large levels of oestrogen. varying HRT doses did not relate to proliferation. A decline in premenopausal breast epithelial proliferation occurs with age.
although the evidence that serum oestradiol levels also decline is lacking (Meyer 1977 : Anderson et al. 1982 : Potten et al. 1988 . sugestin2 that sensitivity of the breast to oestradiol attenuates with ace. This mav result in the failure of low doses of oestrocen. in the form of HRT. to elicit a proliferative response. However. w-e did find that PR expression was higher in both types of HRT user compared with control subjects and there is evidence to suagest that the oestradiol dose required to up-regulate PR expression is lower than that required to induce proliferation within the human breast (Clark-e et al. 1997) . Our findings differ to those presented by Cline et al ( 1996) in which mammary proliferation was significantlv increased in post-menopausal' macaque monkeys administered HRT. However. in that study. the reproductive history of each monkey was unknown and an early-menopause was artificially induced. Ageing of the breast may have a role in attenuating oestrogen responsiveness and could account for the difference in response.
Endogenous and exogenous oestrogens are thought to contribute to breast cancer risk. primarily by increasing breast cell mitogenesis (Howell. 1989 : Pike et al. 1993 . Lona-term HRT use has been shown in multiple studies to be associated with increased breast cancer risk (Brinton et al. 1981 : Colditz et al. 1995 : Beral et al. 1997 and it is thought this may be due to a sustained increase in breast proliferation over several years. Althouah duration of HRT use was considered in our analysis. we w-ould not expect to pick up this effect using this type of study. We have provided evidence that HRT is oestrogenic upon post-menopausal breast tissue as PR expression is raised. We were unable to detect any significant increase in proliferation. but it is possible that patient numbers were insufficient to detect very small increases in normal breast proliferation. Some types of benign breast lesions are associated with an increased risk of subsequently developing cancer (McDivitt et al. 1992 ) and non-malignant lesions have been shown to express the oestrogen receptor (Jaquemier et al. 1982 ). This suggests that benign lesions could respond to exogenous oestrogen and HRT may increase breast cancer risk by promoting the development of these premalignant lesions. initiated earlier in the patient s life. In addition. anti-oestrogens are commonly used in the treatment of breast cancer and have been shown to decrease tumour cell proliferation in *isvo (Clarke et al. 1993) . suggesting that HRT could accelerate the growth and subsequent detection of early. preinvasive malignant lesions.
